Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intervention With Inhaled Treprostinil in Exercise-Induced Pulmonary Hypertension
NCT07837830Phase 1Recruiting
- Sponsor
- The Valley Health System
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of treprostinil in pulmonary hypertension (PH) (2 arms), sponsored by The Valley Health System. Primary endpoint: Change in Exercise Pulmonary Vascular Resistance at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07837830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07837830.